Home » Newsletters » BioWorld

BioWorld

Sep. 8, 1997

View Archived Issues

Genentech Discontinues IGF-1 Development For Diabetes

Senate Begins Debate On FDA Reform; Vote Expected Tuesday

IDEC Expects Rituxan Approval In $45M Fund-Raising Scheme

New Genzyme Cancer Unit Raises $20M In Private Placement Prior To IPO

Phase II Study Successful For Transgenic Blood Protein

BioWorld Phase III Report Product Update Survey

Knocking Out Mutant Virulence Genes In Candida albicans Leaves Mice Alive, Well

Other News To Note